Opthea To Present at Sequire Biotechnology Conference
Opthea Limited announced that Dr. Megan Baldwin, CEO, will present at the Sequire Biotechnology Conference on February 2, 2023, at 10:00 am ET (2:00 am AEDT). Interested participants can register at Sequire's website.
Opthea is focused on developing therapies for retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema. Their lead product, OPT-302, is in pivotal Phase 3 trials aimed at enhancing efficacy when combined with existing treatments.
Investors are cautioned about the inherent risks in biotechnology investments, emphasizing the speculative nature of such opportunities.
- None.
- None.
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.
Dr. Baldwin will present on Thursday, February 2nd at 10:00 am ET (2:00 am AEDT). To access the presentation please register at https://biotech.sequireevents.com.
About Opthea Limited
Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
Inherent risks of Investment in Biotechnology Companies
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
Authorized for release to ASX by Megan Baldwin, CEO & Managing Director
Company & Media Enquiries:
| U.S.A. & International: | Australia: | |
| Timothy E. Morris, CFO | Rudi Michelson | |
| Opthea Limited | Monsoon Communications | |
| Tel: +1 650-400-6874 | Tel: +61 (0) 3 9620 3333 |
Media:
Hershel Berry
Blueprint Life Science Group
Tel: +1 415 505 3749
hberry@bplifescience.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com
FAQ
When is Dr. Megan Baldwin's presentation at the Sequire Biotechnology Conference?
What is the focus of Opthea Limited's research?
What is the current status of Opthea's lead product candidate, OPT-302?
What are the risks associated with investing in Opthea Limited?
How can I register for the Sequire Biotechnology Conference presentation?
